share_log

Arcutis Biotherapeutics | 424B5: Prospectus

SEC announcement ·  Feb 28 16:34
Summary by Moomoo AI
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants...Show More
Arcutis Biotherapeutics, a commercial-stage biopharmaceutical company, has announced the offering of $150,000,000 of its common stock and pre-funded warrants to purchase shares of common stock. The offering is subject to completion and is dated February 28, 2024. The pre-funded warrants will be sold at the public offering price per share of common stock minus $0.0001, multiplied by the number of shares subject to the warrant, with an exercise price of $0.0001 per share. The common stock is listed on the Nasdaq Global Select Market under the symbol 'ARQT.' On February 27, 2024, the last reported sale price of Arcutis' common stock was $10.63 per share. The offering is expected to provide 14,111,006 shares, assuming an assumed public offering price of $10.63 per share. The pre-funded warrants will not be listed on any market, and there is no expectation for a trading market to develop. The offering involves risks, including the absence of an established market for the pre-funded warrants and the potential dilution to existing shareholders. Morgan Stanley, TD Cowen, Guggenheim Securities, Mizuho, and Needham & Company are acting as underwriters for the offering.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more